Skip to content

Insider · CIK 0001235945

WIERENGA WENDALL

director

Files at CYTK (CYTOKINETICS INC). First filing Oct 31, 2024, latest Dec 16, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $306k sold

Signals

This insider’s open-market buys and sells, scored.

ScoreSideCompanyValueSharesHoldings changePrice contextFiled
1Weaksell 410b5-1CYTK
CYTOKINETICS INC
$36k742-3%-
1Weaksell 310b5-1CYTK
CYTOKINETICS INC
$37k742-3%-
13Weaksell 310b5-1CYTK
CYTOKINETICS INC
$233k4,452-15%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jan 2, 2025CYTK
CYTOKINETICS INC
AGrant or award
Common Stock
+127$48.93$6,21424,686Jan 6, 2025
Dec 16, 2024CYTK
CYTOKINETICS INC
MOption exercise
Common Stock10b5-1
+742$7.37$5,46925,301Dec 16, 2024
Dec 16, 2024CYTK
CYTOKINETICS INC
SOpen-market sale
Common Stock10b5-1
-742$48.61$36k24,559Dec 16, 2024
Dec 16, 2024CYTK
CYTOKINETICS INC
MOption exercise
Non-Qualified Stock Option (Right to Buy)derivative10b5-1
-742$0.00$00Dec 16, 2024
Nov 25, 2024CYTK
CYTOKINETICS INC
MOption exercise
Common Stock10b5-1
+742$7.37$5,46925,301Nov 26, 2024
Nov 25, 2024CYTK
CYTOKINETICS INC
SOpen-market sale
Common Stock10b5-1
-742$50.00$37k24,559Nov 26, 2024
Nov 25, 2024CYTK
CYTOKINETICS INC
MOption exercise
Non-Qualified Stock Option (Right to Buy)derivative10b5-1
-742$0.00$0742Nov 26, 2024
Oct 28, 2024CYTK
CYTOKINETICS INC
MOption exercise
Common Stock10b5-1
+4,452$7.37$33k29,011Oct 31, 2024
Oct 28, 2024CYTK
CYTOKINETICS INC
SOpen-market sale
Common Stock10b5-1
-4,452$52.25$233k24,559Oct 31, 2024
Oct 28, 2024CYTK
CYTOKINETICS INC
MOption exercise
Non-Qualified Stock Option (Right to Buy)derivative10b5-1
-4,452$0.00$01,484Oct 31, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

WIERENGA WENDALL: insider trades and track record | InsiderTell